学术急诊医学档案

卷 14 编号 1 (2026)

Early Antiplatelet Therapy in Upper Gastrointestinal Bleeding with Coronary Artery Disease: A Landmark Analysis of MIMIC-IV and eICU-CRD Databases

学术急诊医学档案, 卷 14 编号 1 (2026), 1 十月 2025 , 第 e26 页
https://doi.org/10.22037/aaem.v14i1.3058

摘要

Introduction: The safety of early antiplatelet administration versus withholding in patients with concurrent upper gastrointestinal bleeding (UGIB) and coronary artery disease (CAD) or myocardial infarction (MI) remains unresolved. This study aimed to evaluate the association between early antiplatelet therapy timing and mortality in this population.

Methods: This retrospective cohort study included 3,422 adults with UGIB and concurrent CAD or MI from the Medical Information Mart for Intensive Care IV (MIMIC-IV) dataset (2008-2019). Patients were classified as having antiplatelet therapy ordered within 24 hours (AP-24h; n=1,530), between 24 and 72 hours (AP-24-72h; n=368), or no antiplatelet therapy within 72 hours (No-AP; n=1,524; reference). This study quantified immortal time bias using 72-hour mortality distributions, applied landmark analysis to eliminate this bias, and externally validated findings using the eICU Collaborative Research Database (eICU-CRD). After excluding 87 patients dying within 72 hours, the MIMIC-IV landmark cohort comprised 3,335 patients. The primary outcome was 1-year all-cause mortality from the 72-hour landmark point. eICU-CRD external validation applied the same phenotype and exposure timing; after excluding 137 early deaths, the validation cohort included 2,657 patients. The eICU-CRD outcome was post-landmark hospital mortality.

Results: Landmark analysis demonstrated a 72-hour mortality rate of 3.7% in No-AP versus 1.8% in AP-24h, confirming misclassification of early critically ill patients into the reference group. Adjusted landmark Cox regression showed no significant difference in 1-year all-cause mortality for AP-24h (hazard ratio (HR): 0.910, 95% confidence interval (CI): 0.806-1.027, p=0.125) or AP-24-72h (HR: 0.884, 95% CI: 0.733-1.066, p=0.197) compared with No-AP. In-hospital mortality was similar across groups (8.7-9.8%); adjusted logistic regression showed no significant differences for AP-24h (OR: 1.056, 95% CI: 0.786-1.419, p=0.718) or AP-24-72h (OR: 1.007, 95% CI: 0.646-1.568, p=0.976). Thirty-day mortality was also similar for AP-24h (HR: 0.934, 95% CI: 0.780-1.118, p=0.455) and AP-24-72h (HR: 1.027, 95% CI: 0.785-1.343, p=0.847). In the eICU-CRD validation cohort, post-landmark hospital mortality was 8.69%, 5.07%, and 8.00% for AP-24h, AP-24-72h, and No-AP, respectively. Fully adjusted validation models showed no increased in-hospital mortality for AP-24h (OR: 0.97, 95% CI: 0.62-1.53, p=0.895) or AP-24-72h (OR: 0.74, 95% CI: 0.32-1.69, p=0.469).

Conclusion: After correcting for immortal time bias using landmark analysis, early antiplatelet administration in UGIB patients with CAD or MI was not associated with increased 1-year all-cause mortality or in-hospital mortality in the MIMIC-IV dataset, and this finding was externally supported in the eICU-CRD dataset.

关键词:
  • Gastrointestinal hemorrhage
  • Platelet Aggregation Inhibitors
  • Coronary Artery Disease
  • Cohort Studies

参考

1. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152(1):1-9.

2. Hreinsson JP, Kalaitzakis E, Gudmundsson S, Björnsson ES. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scand J Gastroenterol. 2013;48(4):439-47.

3. Laursen SB, Leontiadis GI, Stanley AJ, Møller MH, Hansen JM, Schaffalitzky de Muckadell OB. Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. Gastrointest Endosc. 2017;85(5):936-44.e3.

4. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama. 2005;293(17):2126-30.

5. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382(9906):1714-22.

6. Gralnek IM, Stanley AJ, Morris AJ, Camus M, Lau J, Lanas A, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. Endoscopy. 2021;53(3):300-32.

7. Acosta RD, Abraham NS, Chandrasekhara V, Chathadi KV, Early DS, Eloubeidi MA, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc. 2016;83(1):3-16.

8. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367.

9. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894-909.

10. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492-9.

11. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. Bmj. 2010;340:b5087.

12. Johnson AEW, Bulgarelli L, Shen L, Gayles A, Shammout A, Horng S, et al. MIMIC-IV, a freely accessible electronic health record dataset. Sci Data. 2023;10(1):1.

13. Goldberger AL, Amaral LA, Glass L, Hausdorff JM, Ivanov PC, Mark RG, et al. PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals. Circulation. 2000;101(23):E215-20.

14. Pollard TJ, Johnson AEW, Raffa JD, Celi LA, Mark RG, Badawi O. The eICU Collaborative Research Database, a freely available multi-center database for critical care research. Sci Data. 2018;5:180178.

15. Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, et al. Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. J Am Coll Cardiol. 2017;70(14):1760-76.

16. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4(3):363-71.

17. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661-79.

18. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.

19. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. Am Stat. 2005;59(4):301-7.

20. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615-25.

21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-7.

22. Hwang JH, Fisher DA, Ben-Menachem T, Chandrasekhara V, Chathadi K, Decker GA, et al. The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest Endosc. 2012;75(6):1132-8.

23. Wu H, Jiang L, Qiu L, Lin Z, Liu H, Lin X, et al. Association between beta-blocker use and outcomes in patients with sepsis-induced myocardial injury: An analysis based on MIMIC-IV and eICU databases. Int J Infect Dis. 2026;165:108458.

24. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet. 2000;356(9238):1318-21.

25. Stanley AJ, Laine L, Dalton HR, Ngu JH, Schultz M, Abazi R, et al. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. Bmj. 2017;356:i6432.

  • 摘要 ##plugins.themes.ojsPlusA.frontend.article.viewed##: 41 ##plugins.themes.ojsPlusA.frontend.article.times##
  • pdf (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 43 ##plugins.themes.ojsPlusA.frontend.article.times##

##plugins.themes.ojsPlusA.frontend.article.downloadstatastics##

##plugins.block.makeSubmission.linkLabel##

##plugins.block.makeSubmission.linkLabel##

SJR

SCImago Journal & Country Rank

COPE

最新一期

消息